Sonova Holding AG stock (CH0012549785): Upcoming earnings on May 18 amid strategic Sennheiser split

Sonova Holding AG (SONVY) is set to report quarterly earnings on May 18, with analysts forecasting $1.44 per share. The company recently announced a strategic decision to refocus on hearing aids by parting ways with Sennheiser.

Sonova Holding AG faces investor attention ahead of its quarterly earnings release scheduled for May 18, 2026. Analysts anticipate earnings of $1.44 per share, according to MarketBeat as of May 2026. Additionally, CEO Eric Bernard revealed a strategic portfolio shift to sharpen focus on hearing care, including plans to separate from Sennheiser, as detailed in a Finanznachrichten interview on May 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova Holding AG
• Sector/industry: Health Technology / Medical Devices
• Headquarters/country: Stäfa, Switzerland
• Core markets: Global hearing solutions
• Key revenue drivers: Hearing aids (92.1%), cochlear implants (7.9%)
• Home exchange/listing venue: SIX Swiss Exchange (SOON), OTC (SONVY)
• Trading currency: CHF (primary), USD (OTC)

Sonova Holding AG: core business model

Sonova Holding AG stands as a global leader in innovative hearing solutions, offering a broad portfolio that includes traditional hearing aids, cochlear implants, and wireless communication systems. The company generates 92.1% of its net sales from hearing aids and 7.9% from cochlear implants, according to data from Marketscreener. Headquartered in Stäfa, Switzerland, Sonova serves markets worldwide with a focus on advanced audiological technologies.

Listed primarily on the SIX Swiss Exchange under ticker SOON and available over-the-counter in the US as SONVY, Sonova provides US investors exposure to the growing hearing health sector. The stock traded at 178.5 CHF on the Swiss Exchange recently, reflecting a 1.54% daily decline as of data from TradingView.

Main revenue and product drivers for Sonova Holding AG

Hearing aids dominate Sonova's revenue stream at 92.1%, driven by demand for innovative devices amid an aging global population. Cochlear implants contribute the remaining 7.9%, targeting patients with severe hearing loss. In the half-year period reported, revenue reached 2.03 billion CHF, surpassing estimates of 2.01 billion CHF, per TradingView data.

Earnings per share for the last half-year stood at 7.07 CHF, beating expectations of 5.89 CHF by 20.03%. Net income rose 59.16% to 332 million CHF from 208.6 million CHF previously. EBITDA reached 984.6 million CHF with a 25.47% margin as of the latest figures from TradingView.

Industry trends and competitive position

The hearing aid market benefits from demographic tailwinds, with rising prevalence of hearing loss in developed economies including the US. Sonova's position as a market leader is bolstered by its technological edge in wireless and implantable solutions. Inclusion in the Euronext Low Carbon 100 Europe PAB index highlights its ESG credentials, as noted on Euronext live data.

Why Sonova Holding AG matters for US investors

US investors can access Sonova via the OTC ticker SONVY, offering exposure to Europe's leading hearing solutions provider amid US healthcare spending growth. The company's global footprint includes significant North American operations, tying its performance to US market dynamics in audiology.

Conclusion

Sonova Holding AG approaches its May 18 earnings with a refocused strategy on core hearing technologies following the Sennheiser decision. Recent financials show revenue and earnings beats, alongside a solid EBITDA margin. Traded accessibly for US investors via SONVY, the stock reflects broader trends in health technology while navigating currency and market volatilities.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.